• 1
    Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D.Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.Ann Rheum Dis2012;71:15249.
  • 2
    Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al.Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.Arthritis Rheum2005;52:40211.
  • 3
    Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al.Patterns of cardiovascular risk in rheumatoid arthritis.Ann Rheum Dis2006;65:160812.
  • 4
    Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al.Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.Ann Rheum Dis2011;70:4827.
  • 5
    Schonbeck U, Libby P.Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?Circulation2004; Suppl 1:II1826.
  • 6
    Robinson JG, Smith B, Maheshwari N, Schrott H.Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.J Am Cardiol2005;46:185562.
  • 7
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med2008;359:2195207.
  • 8
    McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al.Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.Lancet2004;363:201521.
  • 9
    Semb AG, Holme I, Kvien TK, Pedersen TR.Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.Rheumatology (Oxford)2011;50:3249.
  • 10
    Sheng X, Murphy MJ, Macdonald TM, Wei L.Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis.J Rheumatol2012;39:3240.
  • 11
    Kremers HM, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL.The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.Rheumatology (Oxford)2011;50:615.
  • 12
    Melton LJ III.History of the Rochester Epidemiology Project.Mayo Clin Proc1996;71:26674.
  • 13
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum1988;31:31524.
  • 14
    Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM III, Roger VL, et al.The influence of rheumatoid arthritis disease characteristics on heart failure.J Rheumatol2011;38:16016.
  • 15
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation2002;106:3143421.
  • 16
    Turesson C, Jacobsson L, Bergstrom U.Extra-articular rheumatoid arthritis: prevalence and mortality.Rheumatology (Oxford)1999;38:66874.
  • 17
    Semb AG, Kvien TK, Demicco D, Fayyad R, Wun CC, Larosa J, et al.Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.Arthritis Rheum2012;64:283646.
  • 18
    Nissen SE.Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.Am J Cardiol2005;96:61F8F.
  • 19
    Klinke JA, Malek F, Gao M, Holmes D, Frohlich JJ.Reaching target lipid levels in patients at high risk of cardiovascular event: the experience of a Canadian tertiary care lipid clinic.Cent Eur J Public Health2007;15:1069.
  • 20
    Pearson TA, Laurora I, Chu H, Kafonek S.The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Arch Int Med2000;160:45967.
  • 21
    Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG.Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.Ann Rheum Dis. E-pub ahead of print.
  • 22
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, et al.Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) analysis.J Am Coll Cardiol2008;52:91420.
  • 23
    Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al.Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment. A prospective, controlled study.Arthritis Res Ther2006;8:R82.
  • 24
    Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, et al.Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.Ann Rheum Dis2012;71:115762.
  • 25
    Soubrier M, Zerkak D, Dougados M.Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem.J Rheumatol2006;33:17669.
  • 26
    Arts E, Fransen J, Lemmers H, Stalenhoef A, Joosten L, van Riel P, et al.High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study.Arthritis Res Ther2012;14:R116.